Bioniz focuses on developing multi-cytokine inhibitory therapeutics that selectively block redundant cytokines, enabling effective treatment for cancer and autoimmune diseases. Their mission is to complete proof of concept and preclinical studies, seeking partners for clinical trials and regulatory approval. With a commitment to integrity and public health, Bioniz aims to enhance lives globally by discovering novel molecules. Founded in 2009 and based in Irvine, California, the company is dedicated to addressing immuno-inflammatory diseases and revolutionizing cancer treatment.